title: Calcimimetics, parathyroid hormone, and vascular calcification in chronic kidney disease.
abstract: Vascular calcification (VC) occurs frequently in chronic kidney disease, contributing to cardiovascular mortality. Numerous risk factors have been identified, including renal osteodystrophy and bone turnover, with low turnover as a main determinant. Other reports support high turnover as a factor in VC. Calcimimetics, which lower serum parathyroid hormone, and parathyroidectomy each prevented VC induced by five-sixths nephrectomy in rats. These results favor increased bone turnover due to hyperparathyroidism, instead of low turnover, as a factor in VC in uremia.
authors.affiliation: Ospedale Israelitico, Nephrology and Hypertension Unit, Rome, Italy. giorgio.coen@gmail.com
authors.forename: Giorgio
authors.initials: G
authors.lastname: Coen
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016723:Bone Remodeling; D002114:Calcinosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D010281:Parathyroid Hormone / Q000097:blood* / Q000502:physiology; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D014652:Vascular Diseases / Q000209:etiology / Q000473:pathology / Q000628:therapy
chemical_list: D050071:Bone Density Conservation Agents; C470125:PTH protein, human; D010281:Parathyroid Hormone